BDP Home NCI DHHS NIH FIRSTGOV

BDP Home SAIC - Frederick, Inc.

 

 

The Biopharmaceutical Development Program (BDP), located in Frederick, Maryland, was established in 1993 to provide cutting-edge development of monoclonal antibodies, recombinant proteins, peptide and DNA vaccines, virus vaccines and oncolytic virus, gene therapy products, and other biological agents. The BDP is a CGMP-compliant facility that provides complete support from feasibility through development and manufacturing to filing of the regulatory documentation. Since its inception, the BDP has completed over 100 projects, of which 68 have gone into clinical trials.

 

 

Our facilities are designed to be highly flexible, enabling us to work on multiple projects for a variety of different therapies. The BDP is an innovative, dynamic program with a unique mission that differentiates it from other biopharmaceutical contract manufacturers: we concentrate on products that are in early development, beginning with demonstrating product feasibility on the bench through producing Phase I/II clinical supplies and complete testing.

The BDP staff includes more than 125 highly trained and experienced personnel. The combined years of experience in development and manufacturing have led to the production of numerous products that have gone into clinical trials.